Menopausal hormone therapy and risk of endometrial cancer
- 31 July 2014
- journal article
- Published by Elsevier BV in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 142, 83-89
- https://doi.org/10.1016/j.jsbmb.2013.05.001
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- The Epidemiology of Endometrial and Ovarian CancerHematology/Oncology Clinics of North America, 2012
- Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancerCancer Causes & Control, 2011
- Long-term Postmenopausal Hormone Therapy and Endometrial CancerCancer Epidemiology, Biomarkers & Prevention, 2010
- Endometrial Cancer in Postmenopausal Women Using Estradiol–Progestin TherapyObstetrics & Gynecology, 2009
- The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patientsEuropean Journal of Cancer, 2009
- Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976–2004International Journal of Cancer, 2009
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Endometrial cancer risk in estrogen users after switching to estrogen–progestin therapyCancer Causes & Control, 2007
- Tibolone and Endometrial CancerDrug Safety, 2005
- Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancerAmerican Journal of Obstetrics and Gynecology, 2004